Questions About Cancer? 1-800-4-CANCER

Childhood Rhabdomyosarcoma Treatment (PDQ®)

Health Professional Version

Changes to This Summary (04/09/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added Corrigan et al. as reference 2.

Previously Untreated Childhood Rhabdomyosarcoma

Added Hentz et al. as reference 34 and level of evidence 3iiDii.

Added text about an analysis of 1,105 patients with localized parameningeal rhabdomyosarcoma treated on protocols from 1984 to 2004 in North America and Europe that found several prognostic factors that could be used to define subgroups of patients with significantly differing survival rates (cited Merks et al. as reference 47 and level of evidence 3iiiA).

Added text to state that a small series of rhabdomyosarcoma patients with peritoneal dissemination and/or malignant ascites had good outcome with whole-abdomen irradiation using intensity-modulated radiation therapy with dose painting (cited Casey et al. as reference 77 and level of evidence 3iiA).

Added text about a trial of 271 newly diagnosed patients with low-risk rhabdomyosarcoma and found that shorter duration of therapy did not appear to compromise outcome in these patients (cited Walterhouse et al. as reference 116).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: April 9, 2015